SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations

Wan-Ting Yang; Wei-Hsuan Huang; Tsai-Ling Liao; Tzu-Hung Hsiao; Han-Ni Chuang; Po-Yu Liu

doi:10.2147/IDR.S344099

SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations

Infect Drug Resist. 2022 Feb 3:15:373-385. doi: 10.2147/IDR.S344099. eCollection 2022.

Authors

Wan-Ting Yang^#¹, Wei-Hsuan Huang^#¹, Tsai-Ling Liao², Tzu-Hung Hsiao², Han-Ni Chuang², Po-Yu Liu^{1

3

4}

Affiliations

¹ Division of Infection, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
² Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
³ Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
⁴ Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.

^# Contributed equally.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly over the world and claimed million lives. The virus evolves constantly, and a swarm of mutants is a now major concern globally. Distinct variants could have independently converged on same mutation, despite being detected in different geographic regions, which suggested it could confer an evolutionary advantage. E484K has rapidly emerged and has frequently been detected in several SARS-CoV-2 variants of concern. In this study, we review the epidemiology and impact of E484K, its effects on neutralizing effect of several monoclonal antibodies, convalescent plasma, and post-vaccine sera.

Keywords: E484K; SARS-CoV-2 convalescent sera treatment; SARS-CoV-2 variant; coronavirus spike glycoprotein; monoclonal antibody; vaccine.

Publication types

Review